CA2598217A1 - Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin - Google Patents
Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin Download PDFInfo
- Publication number
- CA2598217A1 CA2598217A1 CA002598217A CA2598217A CA2598217A1 CA 2598217 A1 CA2598217 A1 CA 2598217A1 CA 002598217 A CA002598217 A CA 002598217A CA 2598217 A CA2598217 A CA 2598217A CA 2598217 A1 CA2598217 A1 CA 2598217A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- cyr61
- antibody
- level
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 94
- 101150042405 CCN1 gene Proteins 0.000 title claims abstract description 63
- 238000003745 diagnosis Methods 0.000 title claims abstract description 15
- 238000004393 prognosis Methods 0.000 title claims description 5
- 239000000090 biomarker Substances 0.000 title description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 58
- 210000002700 urine Anatomy 0.000 claims abstract description 51
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 31
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 30
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 19
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 19
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 claims abstract description 18
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 claims abstract description 18
- 238000011156 evaluation Methods 0.000 claims abstract description 4
- 239000000523 sample Substances 0.000 claims description 53
- 230000027455 binding Effects 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 22
- 239000013068 control sample Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 11
- 239000007790 solid phase Substances 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 3
- 206010062038 Lip neoplasm Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 201000006721 lip cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 238000012552 review Methods 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 abstract description 7
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000002485 urinary effect Effects 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 42
- 108091007433 antigens Proteins 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 238000001514 detection method Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000000938 luteal effect Effects 0.000 description 10
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 8
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 8
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 230000002491 angiogenic effect Effects 0.000 description 7
- 238000003795 desorption Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000000365 steroidogenetic effect Effects 0.000 description 5
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- -1 152Eu Chemical class 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010006256 Breast hyperplasia Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 206010064390 Tumour invasion Diseases 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 102000039854 CCN family Human genes 0.000 description 2
- 108091068251 CCN family Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007451 Steroid Receptors Human genes 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000011059 lobular neoplasia Diseases 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 102100030009 Azurocidin Human genes 0.000 description 1
- 101710154607 Azurocidin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000782132 Homo sapiens Zinc finger protein 217 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 1
- 102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 1
- 102100024130 Matrix metalloproteinase-23 Human genes 0.000 description 1
- 108050006284 Matrix metalloproteinase-23 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710143583 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- 102100036595 Zinc finger protein 217 Human genes 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000011050 comedo carcinoma Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65411105P | 2005-02-18 | 2005-02-18 | |
| US60/654,111 | 2005-02-18 | ||
| PCT/US2006/005812 WO2006089212A2 (en) | 2005-02-18 | 2006-02-17 | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2598217A1 true CA2598217A1 (en) | 2006-08-24 |
Family
ID=36917123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002598217A Abandoned CA2598217A1 (en) | 2005-02-18 | 2006-02-17 | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7858324B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1849002A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5006802B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101120252A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006214105A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2598217A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006089212A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| WO2006089212A2 (en) * | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| WO2007081385A2 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| WO2007133710A2 (en) | 2006-05-11 | 2007-11-22 | Raindance Technologies, Inc. | Microfluidic devices and methods of use thereof |
| WO2008021123A1 (en) | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8455189B2 (en) * | 2007-03-29 | 2013-06-04 | Jeffrey W. Allard | Use of HE4 for assessment of breast cancers |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| EP4047367A1 (en) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Method for detecting target analytes with droplet libraries |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US9416192B2 (en) | 2008-08-05 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
| ES2471379T3 (es) * | 2008-08-05 | 2014-06-26 | Toray Industries, Inc. | Método para detectar el cáncer |
| CN101747435B (zh) * | 2008-12-18 | 2013-06-19 | 上海市免疫学研究所 | 一种中和cyr61的单克隆抗体(杂交瘤)及其应用 |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| EP2273272A1 (en) | 2009-07-06 | 2011-01-12 | Stichting Katholieke Universiteit | Method for predicting the outcome of chemotherapy in ovarian cancer |
| US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| WO2011079176A2 (en) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| AU2011211698B2 (en) | 2010-02-04 | 2015-07-16 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| PL2532364T3 (pl) | 2010-02-04 | 2016-11-30 | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
| PT2532367T (pt) | 2010-02-04 | 2018-11-09 | Toray Industries | Agente farmacêutico para o tratamento e/ou prevenção do cancro |
| BR112012019098B8 (pt) | 2010-02-04 | 2021-08-17 | Toray Industries | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica |
| MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| EP2534267B1 (en) | 2010-02-12 | 2018-04-11 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| EP2622103B2 (en) | 2010-09-30 | 2022-11-16 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
| EP3859011A1 (en) | 2011-02-11 | 2021-08-04 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
| EP3736281A1 (en) | 2011-02-18 | 2020-11-11 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
| US9556470B2 (en) | 2011-06-02 | 2017-01-31 | Raindance Technologies, Inc. | Enzyme quantification |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| WO2012174498A2 (en) * | 2011-06-16 | 2012-12-20 | Pitari Giovanni M | Biomarkers for epithelial cancer diagnosis and treatment |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013018894A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| PT2741085T (pt) | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| JP6015448B2 (ja) | 2011-08-04 | 2016-10-26 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| ES2609859T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición de fármaco para el tratamiento y/o la prevención del cáncer |
| MX351414B (es) | 2011-08-04 | 2017-10-13 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. |
| MX348578B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| WO2013018883A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| EP3495817B1 (en) | 2012-02-10 | 2024-10-16 | Bio-Rad Laboratories, Inc. | Molecular diagnostic screening assay |
| WO2013125640A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2013125636A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| BR112014021099A2 (pt) | 2012-02-21 | 2020-12-01 | Toray Industries, Inc | anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo |
| RU2631804C2 (ru) | 2012-02-21 | 2017-09-26 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения или профилактики рака |
| CA2869120C (en) | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| MX357965B (es) | 2012-03-30 | 2018-08-01 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. |
| WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
| KR102056654B1 (ko) | 2012-07-19 | 2019-12-17 | 도레이 카부시키가이샤 | 암의 검출 방법 |
| MX358772B (es) | 2012-07-19 | 2018-09-04 | Toray Industries | Metodo para detectar cancer. |
| WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
| PL3031826T3 (pl) | 2013-08-09 | 2019-03-29 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| CN105396136B (zh) * | 2015-11-23 | 2018-10-30 | 上海交通大学医学院附属第九人民医院 | CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用 |
| CN107422125A (zh) * | 2016-05-23 | 2017-12-01 | 中国医学科学院肿瘤医院 | 与肌层浸润性膀胱癌相关的尿液蛋白质标志物 |
| EP3364190A1 (en) * | 2017-02-20 | 2018-08-22 | Panka Cancer Research AG | Method of detecting cancer or cancer cells |
| US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
| CN108752454B (zh) * | 2018-06-19 | 2021-07-20 | 中山大学孙逸仙纪念医院 | 一种人CYR61蛋白Ser188位点磷酸化抗原、抗体及其制备方法和应用 |
| CN111426835A (zh) * | 2019-01-10 | 2020-07-17 | 北京师范大学 | 肝转移癌相关的尿液蛋白标记物的筛选及其用途 |
| CN113777315A (zh) * | 2020-06-09 | 2021-12-10 | 首都医科大学附属北京世纪坛医院 | 尿液泛素样蛋白isg15及其多肽片段在烧伤中的应用 |
| CN112147337B (zh) * | 2020-08-19 | 2024-05-28 | 德赛诊断系统(上海)有限公司 | 一种富含半胱氨酸蛋白61高敏化学发光检测试剂盒及其制备和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| AU2001271365A1 (en) | 2000-06-21 | 2002-01-02 | Wyeth | Cyr61 as a target for treatment and diagnosis of breast cancer |
| EP1322778A4 (en) * | 2000-09-29 | 2005-06-15 | Wyeth Corp | APPLICATION OF CYR61 IN THE TREATMENT AND DIAGNOSIS OF HUMAN UTERUS MYOMENIC |
| US20040086504A1 (en) * | 2001-06-21 | 2004-05-06 | Deepak Sampath | Cyr61 as a target for treatment and diagnosis of breast cancer |
| WO2003009814A2 (en) * | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| EP1434993B1 (en) | 2001-09-18 | 2013-04-24 | Fibrogen, Inc. | Methods of assaying connective tissue growth factor |
| JP2003177126A (ja) * | 2001-12-13 | 2003-06-27 | Kenichi Katsube | Ｃｃｎファミリー蛋白質活性制御剤のスクリーニング方法 |
| US20040241653A1 (en) * | 2001-12-31 | 2004-12-02 | Elena Feinstein | Methods for identifying marker genes for cancer |
| EP2083270B1 (en) * | 2003-03-27 | 2019-06-12 | Children's Hospital Medical Center | A method and kit for detecting the early onset of renal tubular cell injury |
| JP2004315480A (ja) * | 2003-04-21 | 2004-11-11 | Yoshiyuki Kakehi | 前立腺疾患治療用医薬組成物 |
| WO2006089212A2 (en) * | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
-
2006
- 2006-02-17 WO PCT/US2006/005812 patent/WO2006089212A2/en not_active Ceased
- 2006-02-17 JP JP2007556362A patent/JP5006802B2/ja not_active Expired - Fee Related
- 2006-02-17 AU AU2006214105A patent/AU2006214105A1/en not_active Abandoned
- 2006-02-17 US US11/815,831 patent/US7858324B2/en active Active
- 2006-02-17 CA CA002598217A patent/CA2598217A1/en not_active Abandoned
- 2006-02-17 EP EP06735465A patent/EP1849002A4/en not_active Ceased
- 2006-02-17 CN CNA2006800051581A patent/CN101120252A/zh active Pending
-
2010
- 2010-12-23 US US12/977,348 patent/US20110189700A1/en not_active Abandoned
-
2016
- 2016-08-29 US US15/249,829 patent/US20170205419A1/en not_active Abandoned
-
2018
- 2018-06-26 US US16/018,254 patent/US20190154693A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006089212A3 (en) | 2007-01-11 |
| US20110189700A1 (en) | 2011-08-04 |
| US20170205419A1 (en) | 2017-07-20 |
| EP1849002A4 (en) | 2008-08-20 |
| CN101120252A (zh) | 2008-02-06 |
| US20080286811A1 (en) | 2008-11-20 |
| WO2006089212A2 (en) | 2006-08-24 |
| EP1849002A2 (en) | 2007-10-31 |
| AU2006214105A1 (en) | 2006-08-24 |
| US20190154693A1 (en) | 2019-05-23 |
| JP5006802B2 (ja) | 2012-08-22 |
| US7858324B2 (en) | 2010-12-28 |
| JP2008530582A (ja) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7858324B2 (en) | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin | |
| US20190361028A1 (en) | Free ngal as a biomarker for cancer | |
| US8685659B2 (en) | Method for diagnosis and prognosis of epithelial cancers | |
| US20100209944A1 (en) | Adamts-7 as a biomarker for cancers of epithelial origin | |
| CA2552882C (en) | Methods for diagnosis and prognosis of cancers of epithelial origin | |
| WO2009017475A1 (en) | Methods for diagnosis and prognosis of epithelial cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20170419 |